Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt

Psychopharmacology

Volumn 197, Issue 3, 2008, Pages 371-377

  West, Robert ^a   Baker, Christine L ^b   Cappelleri, Joseph C ^b   Bushmakin, Andrew G ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Abstinent; Alpha4 beta2 nicotinic acetylcholine receptor partial agonist (nAChR); Craving; Minnesota Nicotine Withdrawal Scale (MNWS); Modified Cigarette Evaluation Questionnaire (mCEQ); Nicotine; Non abstinent; Reward; Varenicline; Withdrawal

Indexed keywords

AMFEBUTAMONE; NICOTINE; PLACEBO; VARENICLINE;

ABSTINENCE; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SATISFACTION; SMOKING; SMOKING CESSATION; STATISTICAL SIGNIFICANCE; SUSTAINED DRUG RELEASE; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AFFECT; AGED; BENZAZEPINES; BUPROPION; CLINICAL TRIALS, PHASE III AS TOPIC; DELAYED-ACTION PREPARATIONS; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MOTIVATION; MULTICENTER STUDIES AS TOPIC; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 43149085570     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-1041-3     Document Type: Article

References (19)

1. Bradley E, Tibshirani R (1993) An introduction to the bootstrap. Chapman & Hall, New York
2. Cahill K, Stead L, Lancaster T (2007) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev: CD006103
3. Cappelleri J, Bushmakin A, Baker C, Merikle E, Olufade A, Gilbert D (2005) Revealing the multidimensional framework of the Minnesota Nicotine Withdrawal Scale. Curr Med Res Opin 21:749-760
4. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG (2007) Confirmatory factor analyses and reliability of the modified Cigarette Evaluation Questionnaire. Addict Behav 32:912-923
5. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT (2005) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474-3477
6. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47-55
7. Hughes JR (2007) Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 9:315-327
8. Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289-294
9. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW (1991) Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry 48:52-59
10. Hughes JR, Higgins ST, Bickel WK (1994) Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 89:1461-1470
11. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56-63
12. Nides M, Oncken C, Gonzales D, Rennard S, Watsky E, Anziano R, Reeves K (2006) Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166:1561-1568
13. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K (2006) Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166:1571-1577
14. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE (2007) Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-994
15. Rose JE, Westman EC, Behm FM, Johnson MP, Goldberg JS (1999) Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan. Pharmacol Biochem Behav 62:165-72
16. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296:64-71
17. West R (2006) New approaches to smoking cessation. Available at: http://www.ttmed.com/respiratory/print.cfm?ID_Dis=8&ID_Cou=23&ID_Art= 1598 Accessed April 23rd, 2007
18. West R, Ussher M, Evans M, Rashid M (2006) Assessing DSM-IV nicotine withdrawal symptoms: a comparison and evaluation of five different scales. Psychopharmacology (Berl) 184:619-627
19. Williams K, Reeves K, Billing C, Pennington A, Gong J (2007) A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 23:793-801